133 related articles for article (PubMed ID: 26916808)
1. Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy.
Mansfield AS; Dong H
Clin Pharmacol Ther; 2016 Sep; 100(3):220-2. PubMed ID: 26916808
[TBL] [Abstract][Full Text] [Related]
2. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Expression in Lung Cancer.
Yu H; Boyle TA; Zhou C; Rimm DL; Hirsch FR
J Thorac Oncol; 2016 Jul; 11(7):964-75. PubMed ID: 27117833
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
Chen L; Zhu XZ; Zhao SJ; Yang QW
Lancet Oncol; 2024 Jun; 25(6):e233. PubMed ID: 38821094
[No Abstract] [Full Text] [Related]
5. RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
Wu X; Zhang B
J Natl Cancer Inst; 2024 Jun; ():. PubMed ID: 38851882
[No Abstract] [Full Text] [Related]
6. RE: Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
Taki T; Ishii G
J Natl Cancer Inst; 2024 Jun; ():. PubMed ID: 38848476
[No Abstract] [Full Text] [Related]
7. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
Passiglia F; Bronte G; Bazan V; Natoli C; Rizzo S; Galvano A; Listì A; Cicero G; Rolfo C; Santini D; Russo A
Oncotarget; 2016 Apr; 7(15):19738-47. PubMed ID: 26918451
[TBL] [Abstract][Full Text] [Related]
8. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Mansfield AS; Aubry MC; Moser JC; Harrington SM; Dronca RS; Park SS; Dong H
Ann Oncol; 2016 Oct; 27(10):1953-8. PubMed ID: 27502709
[TBL] [Abstract][Full Text] [Related]
9. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
10. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Rehman JA; Han G; Carvajal-Hausdorf DE; Wasserman BE; Pelekanou V; Mani NL; McLaughlin J; Schalper KA; Rimm DL
Mod Pathol; 2017 Mar; 30(3):340-349. PubMed ID: 27834350
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
12. Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy.
Fang XN; Fu LW
Recent Pat Anticancer Drug Discov; 2016; 11(2):141-51. PubMed ID: 26916881
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer.
Pennell NA
JAMA Oncol; 2016 May; 2(5):569-570. PubMed ID: 26986805
[No Abstract] [Full Text] [Related]
14. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Villaruz LC; Socinski MA
Clin Pharmacol Ther; 2016 Sep; 100(3):212-4. PubMed ID: 27090296
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
Smit EF; van den Heuvel MM
Lancet; 2016 Apr; 387(10030):1795-6. PubMed ID: 26972842
[No Abstract] [Full Text] [Related]
16. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
17. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
18. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
[TBL] [Abstract][Full Text] [Related]
19. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Grigg C; Rizvi NA
J Immunother Cancer; 2016; 4():48. PubMed ID: 27532023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
